JP7758906B2 - セラチオペプチダーゼ、マンノースまたはその誘導体および任意に抗感染薬剤を使用する医薬組成物ならびに処置の方法 - Google Patents

セラチオペプチダーゼ、マンノースまたはその誘導体および任意に抗感染薬剤を使用する医薬組成物ならびに処置の方法

Info

Publication number
JP7758906B2
JP7758906B2 JP2022552748A JP2022552748A JP7758906B2 JP 7758906 B2 JP7758906 B2 JP 7758906B2 JP 2022552748 A JP2022552748 A JP 2022552748A JP 2022552748 A JP2022552748 A JP 2022552748A JP 7758906 B2 JP7758906 B2 JP 7758906B2
Authority
JP
Japan
Prior art keywords
mannose
serratiopeptidase
pharmaceutical composition
solution
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022552748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515880A (ja
JP2023515880A5 (https=
Inventor
パテル，ニメシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023515880A publication Critical patent/JP2023515880A/ja
Publication of JP2023515880A5 publication Critical patent/JP2023515880A5/ja
Application granted granted Critical
Publication of JP7758906B2 publication Critical patent/JP7758906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/2404—Serralysin (3.4.24.40)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022552748A 2020-03-02 2021-03-02 セラチオペプチダーゼ、マンノースまたはその誘導体および任意に抗感染薬剤を使用する医薬組成物ならびに処置の方法 Active JP7758906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984135P 2020-03-02 2020-03-02
US62/984,135 2020-03-02
PCT/US2021/020411 WO2021178371A1 (en) 2020-03-02 2021-03-02 A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents

Publications (3)

Publication Number Publication Date
JP2023515880A JP2023515880A (ja) 2023-04-14
JP2023515880A5 JP2023515880A5 (https=) 2024-03-07
JP7758906B2 true JP7758906B2 (ja) 2025-10-23

Family

ID=77463237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552748A Active JP7758906B2 (ja) 2020-03-02 2021-03-02 セラチオペプチダーゼ、マンノースまたはその誘導体および任意に抗感染薬剤を使用する医薬組成物ならびに処置の方法

Country Status (9)

Country Link
US (1) US20210268075A1 (https=)
EP (1) EP4114407A4 (https=)
JP (1) JP7758906B2 (https=)
CN (1) CN115361953A (https=)
AU (1) AU2021229482A1 (https=)
BR (1) BR112022016132A2 (https=)
CA (1) CA3164767A1 (https=)
WO (1) WO2021178371A1 (https=)
ZA (1) ZA202209623B (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007099639A (ja) 2005-09-30 2007-04-19 Towa Chem Ind Co Ltd 除菌洗浄剤
US20090317364A1 (en) 2006-07-10 2009-12-24 Chandrakant Laxminarayan Rathi Novel compositions for prevention and treatment of mastitis and metritis
JP2015522702A (ja) 2012-07-24 2015-08-06 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 多量体マンノシド類、その製造方法および医薬としての使用
JP2016518441A (ja) 2013-05-14 2016-06-23 プロバイオティカル・ソシエタ・ペル・アチオニＰｒｏｂｉｏｔｉｃａｌ Ｓ．Ｐ．Ａ． 再発性膀胱炎の予防的および／または治療的処置に使用するための乳酸菌含有組成物
JP2016520618A (ja) 2013-05-30 2016-07-14 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細菌感染症を治療するための化合物及び方法
US20190000908A1 (en) 2017-06-29 2019-01-03 Hms Laboratories Ltd. Compositions and methods for treating and/or preventing a urinary tract infection
WO2019018087A1 (en) 2017-07-18 2019-01-24 Dow Global Technologies Llc DISPERSION METHOD OF BIOFILM
CN116115768A (zh) 2022-12-01 2023-05-16 西南民族大学 一种抗菌剂及其制备方法和应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007099639A (ja) 2005-09-30 2007-04-19 Towa Chem Ind Co Ltd 除菌洗浄剤
US20090317364A1 (en) 2006-07-10 2009-12-24 Chandrakant Laxminarayan Rathi Novel compositions for prevention and treatment of mastitis and metritis
JP2015522702A (ja) 2012-07-24 2015-08-06 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 多量体マンノシド類、その製造方法および医薬としての使用
JP2016518441A (ja) 2013-05-14 2016-06-23 プロバイオティカル・ソシエタ・ペル・アチオニＰｒｏｂｉｏｔｉｃａｌ Ｓ．Ｐ．Ａ． 再発性膀胱炎の予防的および／または治療的処置に使用するための乳酸菌含有組成物
JP2016520618A (ja) 2013-05-30 2016-07-14 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細菌感染症を治療するための化合物及び方法
US20190000908A1 (en) 2017-06-29 2019-01-03 Hms Laboratories Ltd. Compositions and methods for treating and/or preventing a urinary tract infection
WO2019018087A1 (en) 2017-07-18 2019-01-24 Dow Global Technologies Llc DISPERSION METHOD OF BIOFILM
CN116115768A (zh) 2022-12-01 2023-05-16 西南民族大学 一种抗菌剂及其制备方法和应用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AAPS PharmSciTech，2014年08月30日，Vol. 16, No. 1，p.59-66，DOI: 10.1208/s12249-014-0201-0
American journal of veterinary research，2000年，Vol. 61，No. 4，p.446-449
Antimicrobial Agents and Chemotherapy，1993年12月，Vol. 37, No. 12，p.2618-2621，DOI: 10.1128/AAC.37.12.2618
Environmental Microbiology Reports，2017年，Vol. 9，No. 6，p.779-787，DOI: 10.1111/1758-2229.12595
INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION，2014年，vol. 4, no. 1，p. 5-14
Journal of Bacteriology and Virology，2016年，Vol. 46，No. 2，p.57-62，DOI: 10.4167/jbv.2016.46.2.57
Journal of microbiology, immunology, and infection，2006年08月，Vol. 39，No. 4，p.278-91
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE，2017年，vol. 13, no. 7，pages2371-2384
PloS one，2008年04月，Vol. 3，No. 4，p.e2040
Reviews in Medical Microbiology，2011年10月，Vol. 22, No. 4，p.96-101，DOI: 10.1097/MRM.0b013e3283494749
Urol Res，1983年，11，p.97-102
Veterinary Microbiology，2015年01月，Vol. 175，No. 1，p.114-122，DOI: 10.1016/j.vetmic.2014.11.012

Also Published As

Publication number Publication date
US20210268075A1 (en) 2021-09-02
BR112022016132A2 (pt) 2023-01-10
ZA202209623B (en) 2023-12-20
EP4114407A1 (en) 2023-01-11
AU2021229482A1 (en) 2022-07-28
WO2021178371A1 (en) 2021-09-10
CN115361953A (zh) 2022-11-18
CA3164767A1 (en) 2021-09-10
JP2023515880A (ja) 2023-04-14
EP4114407A4 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
RU2607660C2 (ru) Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент
CN109640977B (zh) 大麻二酚组合物及其用途
Sautter et al. Serratia marcescens meningitis associated with a contaminated benzalkonium chloride solution
ES2661000T3 (es) Uso antibacteriano de salicilanilidas halogenadas
Yang et al. Biofilm tolerance, resistance and infections increasing threat of public health
CN107108624B (zh) 用于治疗耐药性细菌感染的组合疗法
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
CN116236479A (zh) Su3327在制备增强多黏菌素抗细菌感染效力的药物中的用途
JP7758906B2 (ja) セラチオペプチダーゼ、マンノースまたはその誘導体および任意に抗感染薬剤を使用する医薬組成物ならびに処置の方法
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
CN107714678A (zh) 紫檀芪在制备mcr‑1酶抑制剂中的应用
US20230364065A1 (en) Antibiotic combination therapies
Girard et al. The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections
CN106132411A (zh) 包含抗菌剂的药物组合物
CN106029068A (zh) 包含抗菌剂的药物组合
WO2022189364A1 (en) Associations of fosfomycin and colistin for use against biofilm-associated bacterial infections
Collignon 11: Antibiotic resistance
LeFrock et al. Effectiveness of cefotaxime in gram-negative meningitis
Tiwari et al. Use of antibiotics: From preceding to contemporary.
Roberts Antimicrobial agents used in wound care
US10314813B2 (en) Antimicrobial compositions for Clostridium difficile
RU2614730C1 (ru) Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
KR20210082009A (ko) 시스-자스몬을 포함하는 바이오필름 형성 억제용 조성물
CN111569079B (zh) 一种抗葡萄球菌感染的抗体抗生素联合制剂
CN102125562A (zh) 一种治疗超级细菌的注射用药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250822

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250828

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250829

R150 Certificate of patent or registration of utility model

Ref document number: 7758906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150